Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 763 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CF - Cystic Fibrosis Clear all
Completed No phase listed Observational

Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.

NCT04038710
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Triple combination therapy
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 30, 2026, 7:03 AM EDT
Enrolling by invitation Phase 3 Interventional

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

NCT05844449
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
1 Year and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
18
States / cities
Orange, California • Palo Alto, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 7:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nuclear Morphology of Breast Cells in Ductal Lavage

NCT00259597
View directory record Official record
Conditions
Benign Breast Disease
Interventions
breast ductal lavage
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 30, 2026, 7:03 AM EDT
Recruiting No phase listed Observational

ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health

NCT07505797
View directory record Official record
Conditions
Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms, Breast Disease, Breast Cancer Female, Breast Pain, Breast Cancer Invasive, Breast Cancer Detection
Interventions
ATUSA 3D Automated Breast Ultrasound System
Device
Lead sponsor
iSono Health, Inc.
Industry
Eligibility
18 Years to 94 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Sacramento, California • Cypress, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Not applicable Interventional Results available

Ketone Supplementation in Cystic Fibrosis

NCT04938726
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ketone Monoester
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Not applicable Interventional Results available

MN4000 for Treatment of CF and MND Patients in the Home Setting

NCT03797677
View directory record Official record
Conditions
Cystic Fibrosis, Motor Neuron Disease, Airway Clearance Impairment
Interventions
MN 4000
Device
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 30, 2026, 7:03 AM EDT
Enrolling by invitation No phase listed Observational

Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening

NCT04579211
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
urine lipoarabinomannan (LAM)
Diagnostic Test
Lead sponsor
Jerry A. Nick, M.D.
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Not applicable Interventional

Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention

NCT04923880
View directory record Official record
Conditions
Cystic Fibrosis, Quality of Life
Interventions
Implementation of Primary Palliative Care Intervention in CF Centers
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 2 Interventional

Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis

NCT00274391
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
7% NaCl, Amiloride HCl
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
14 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2006 · Synced Oct 30, 2026, 7:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glycemic Monitoring in Cystic Fibrosis

NCT02211235
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 25 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

NCT02516410
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661 plus ivacaftor combination, Ivacaftor, Placebo (matched to VX-661 plus ivacaftor combination), Placebo (matched to ivacaftor)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 30, 2026, 7:03 AM EDT
Completed No phase listed Observational

Segmental Bronchoalveolar Lavage

NCT00001618
View directory record Official record
Conditions
Asthma, Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 4 Interventional Results available

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

NCT01429259
View directory record Official record
Conditions
Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
Interventions
meropenem
Drug
Lead sponsor
Joseph Kuti
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Hartford, Connecticut • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

NCT02279498
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
Liprotamase, porcine (pig) PERT
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
32
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 30, 2026, 7:03 AM EDT
Completed No phase listed Observational

Mapping Chemical and Microbiological Heterogeneity Throughout Explanted Cystic Fibrosis Lung Specimens

NCT02128711
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Not applicable Interventional

Feasibility of a Goal-based Agenda Setting Intervention

NCT04696484
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Disease
Interventions
coopeRATE Prompt
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Denver, Colorado • Kansas City, Kansas • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients

NCT01270347
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
MP-376 (Levofloxacin Solution for Inhalation), TIS (Tobramycin Inhalation Solution)
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
99
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis

NCT02613884
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Treatment
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
36 Months to 18 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

NCT01746784
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
N6022, Normal saline
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
17
States / cities
Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 30, 2026, 7:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)

NCT02477319
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Observational
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
12 Years and older
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects

NCT02134353
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled mannitol, Placebo Comparator: Arm B - Control
Drug
Lead sponsor
Syntara
Industry
Eligibility
18 Years to 99 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 2 Interventional

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

NCT07108153
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
SION-719, Placebo-to-match SION-719
Drug
Lead sponsor
Sionna Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Denver, Colorado • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 7:03 AM EDT
Completed Phase 4 Interventional Results available

Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

NCT03502070
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, Tobi Podhaler
Drug · Device
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Miami, Florida • Orlando, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 30, 2026, 7:03 AM EDT
Completed No phase listed Observational

Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation

NCT02480270
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 30, 2026, 7:03 AM EDT